October 2010 Blog Posts (64)

Search Blog Posts

Australia Establishes National Asbestos Management Review

The Australian Minister for Workplace Relations, Senator Chris Evans, today announced the establishment of a national review into the management of asbestos and the Government’s intention to ratify several international labor organization treaties.



The Australian Asbestos Management Review will assess current activities in the area of asbestos management and research and make recommendations for the development of a national strategic plan to improve asbestos… Continue

Added by Peter Hofland, PhD on October 29, 2010 at 9:00am — No Comments

ACS funds study to evaluate whether culturally sensitive outreach and education can improve participation in genetic counseling for cancer risk among Latinas

Breast cancer is the leading cause of cancer death for Latinas in the U.S., according to the American Cancer Society. Genetic epidemiologic research conducted by Jeffrey Weitzel, M.D., director of the Division of Clinical Cancer Genetics at City of Hope, a leading research and treatment center for cancer and other life-threatening diseases, has shown that certain mutations in the BRCA genes are prevalent among immigrant Latinas — women of Latin American and/or Spanish descent — with… Continue

Added by Peter Hofland, PhD on October 28, 2010 at 11:30am — No Comments

'Smart drug' Targets New Mutation And Dramatically Shrinks Aggressive Sarcoma And Lung Cancer

A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine (NEJM).



A second patient who had a similar tumor that was not fueled by the mutant protein, called ALK (named for the first… Continue

Added by Peter Hofland, PhD on October 27, 2010 at 11:30am — No Comments

Watchdog Does Not Recommend Ofatumumab, Temsirolimus, and Bendamustine For Use In The UK

The United Kingdom's health watchdog, the National Institute for Health and Clinical Excellence (NICE) earlier today published three separate pieces of guidance for the NHS on the use of the cancer drugs ofatumumab (Arzerra®, GlaxoSmithKline), temsirolimus (… Continue

Added by Peter Hofland, PhD on October 27, 2010 at 10:00am — No Comments

Caution Regarding Use Of Erythropoiesis-Stimulating Agents In Cancer Patients Recommended In New Guideline

An updated joint guideline by the American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia.



While… Continue

Added by Peter Hofland, PhD on October 25, 2010 at 11:30am — No Comments

Childhood Cancer Survivors Face Long-term Risk Of Gastrointestinal Complications, Study From Dana-Farber Finds

People treated for cancer when they were children have a higher-than-average risk of gastrointestinal problems — some mild, some quite severe — in the years following treatment, according to a study to be presented at the 42nd Congress of the International Society of Paediatric Oncology (SIOP) in Boston on Sunday, October 24, 2010.



Investigators at Dana-Farber/Children's Hospital Cancer Center and… Continue

Added by Peter Hofland, PhD on October 22, 2010 at 4:30pm — No Comments

Parents Experience Difficulty With Consent Process In Pediatric Cancer Trials, Study From Dana-Farber Shows

Compared with adult cancer patients, parents of children with cancer were more likely to be dissatisfied with the informed consent process for participating in clinical trials, according to a study from Dana-Farber/Children's Hospital Cancer Center.



The findings will be presented at the 42nd Congress of the International Society of Paediatric Oncology (SIOP) in Boston on Saturday, October. 23,… Continue

Added by Peter Hofland, PhD on October 22, 2010 at 4:30pm — No Comments

New Research Shows That Girls With Ovarian Germ-cell Tumors Can Safely Skip Chemotherapy Unless Disease Recurs

Researchers from Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) have found that as many as 50% of young girls treated for germ-cell ovarian tumors might safely be spared chemotherapy using a "watch and wait" strategy to determine if the follow-up treatment is needed.



In contrast… Continue

Added by Peter Hofland, PhD on October 22, 2010 at 1:30pm — No Comments

Dana-Farber Identifies Barriers To Successful Treatment Of Children With Sarcoma In Low-income Countries

Raising the survival rate of children with sarcoma in low-income countries will require steps to diagnose the disease sooner, train cancer pathologists, expand radiation therapy services, create multi-specialty teams to review each case, and other actions, according to an international study led by Dana-Farber/Children's Hospital Cancer Center researchers.



The findings were presented at the 42nd Congress of the… Continue

Added by Peter Hofland, PhD on October 22, 2010 at 1:00pm — No Comments

Breast Cancer Awareness Month: 10 Tips For Breast Cancer Survivors

Throughout October, National Breast Cancer Awareness Month, experts from

Fred Hutchinson Cancer Research Center and its clinical care partner, the Seattle Cancer Care Alliance, are offering weekly research-based tip sheets regarding breast cancer prevention, screening and early detection, treatment and survivorship.



Today's tip sheet, the fourth and final in the series, is '10… Continue

Added by Peter Hofland, PhD on October 22, 2010 at 10:30am — No Comments

Combining Stem-Cell And Gene-Therapy Techniques To Tackle Fanconi Anemia, A fatal Genetic Blood Disease

The National Institutes of Health has awarded a three-year, $3.9 million grant to Children's Hospital Boston researchers and their colleagues to develop a therapy to treat Fanconi anemia, a fatal genetic blood disease.



The researchers will investigate new ways to create induced pluripotent stem (iPS) cells from a patient's skin or other tissue and transform them into genetically… Continue

Added by Peter Hofland, PhD on October 22, 2010 at 7:00am — No Comments

Dasatinib Receives Positive Opinion From The European Medicines Agency

Earlier today dasatinib (Sprycel®, Bristol-Myers Squibb) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive Chronic Myelogenous Leukaemia in Chronic Phase (CML-CP).



CML is a slow-growing type of leukemia in which the body produces an uncontrolled number of abnormal white blood cells. CML is most commonly diagnosed in those aged… Continue

Added by Peter Hofland, PhD on October 22, 2010 at 7:00am — No Comments

FDA Approves Trastuzumab In Combination With Cisplatin + Capecitabine or 5-FU For The Treatment Of HER2 Overexpressing Gastroesophageal Junction Adenocarcinoma

The U. S. Food and Drug Administration earlier this month granted approval for trastuzumab (Herceptin®, Genentech, Inc.), in combination with cisplatin and a fluoropyrimidine (capecitabine or 5-fluorouracil), for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarcinoma, who have not received prior treatment for metastatic disease.



The approval is based on a significant improvement in median overall… Continue

Added by Peter Hofland, PhD on October 21, 2010 at 7:30pm — No Comments

Cancer Prevention Institute Wins $2.6M Grant To Study Cancer Risk in California

The National Cancer Institute (NCI) has awarded a $2.6 million grant to the Cancer Prevention Institute of California (CPIC). The award, which is part of a larger collaborative grant, supports CPIC's study of body size and cancer risk within the California Teachers Study, one of the largest longitudinal studies of women's health.



Formerly known as the… Continue

Added by Peter Hofland, PhD on October 21, 2010 at 4:00pm — No Comments

Physicians View FDA-Required REMS Program as a Potential Barrier to Prescribing Erythropoiesis-Stimulating Agents: Possible Decline In Prescribing

Sermo, the largest online community where over 115,000 practicing physicians discuss a wide range of issues from clinical cases to advice about drugs and practice management, today published a free Sermo Report titled, 'Physician Participation in the ESA REMS Program.' The report covers physician perceptions and participation rates in the FDA-required… Continue

Added by Peter Hofland, PhD on October 21, 2010 at 11:00am — No Comments

Research Shows Lack Of Awareness And Cost Negatively Impacts Vaccination Rates: 90% Of Young Canadian Women Not Vaccinated Against Cervical Cancer

Young Canadian women are leaving themselves vulnerable to cervical cancer because they are unaware of the benefits of vaccination and feel the cost of the vaccine is prohibitive, according to a survey of young women and mothers released today.



Lack of Awareness is a major problem. The survey showed that 68% of young Canadian women between the ages of 18 and 25 have not received the cervical cancer vaccination because they do not know enough about it. A further… Continue

Added by Peter Hofland, PhD on October 21, 2010 at 8:00am — No Comments

Bioelectrical Signals Turn Stem Cells' Progeny Cancerous – Discovery May Lead to New Cancer Treatment

Biologists at Tufts University School of Arts and Sciences have discovered that a change in membrane voltage in newly identified ‘instructor cells’ can cause stem cells' descendants to trigger melanoma-like growth in pigment cells. The Tufts team also found that this metastatic transformation is due to changes in serotonin transport. The discovery could aid in the prevention and treatment of diseases like cancer and… Continue

Added by Peter Hofland, PhD on October 19, 2010 at 11:30am — No Comments

Proton Therapy Safe, Effective For Early-stage Lung Cancer Patients

Proton beam therapy is safe and effective and may be superior to other conventional treatments for Stage I inoperable non-small cell lung cancer (NSCLC) patients, according to a study in the October 2010 issue of the International Journal of Radiation Oncology, Biology, Physics, the official journal of the American Society for Radiation Oncology (… Continue

Added by Peter Hofland, PhD on October 19, 2010 at 10:00am — No Comments

National Institutes of Health (NIH) Awards Nearly $3 Million For Ground-Breaking Immunotherapy Clinical Study

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit, USA, have received a nearly $3 million, five-year research project (RO1) grant from the National Institutes of Health to study a potentially ground-breaking immunotherapy treatment for women with one of the deadliest forms of breast cancer – triple-negative breast cancer. The research is exclusive to the… Continue

Added by Peter Hofland, PhD on October 18, 2010 at 2:00pm — No Comments

Preclinical Data Demonstrates That NKTR-181 Has Reduced Abuse Liability with Equivalent Analgesia to Oxycodone

New preclinical data presented todat demonstrates that NKTR-181 (Nektar Therapeutics), a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine. These data were presented during the poster session entitled "Chronic and Cancer Pain" held today at the American Society of Anesthesiologists (ASA 2010) Annual Meeting in San Diego,… Continue

Added by Peter Hofland, PhD on October 17, 2010 at 5:30pm — No Comments

Featured Blog Posts

View All

Latest Blog Posts

Most Popular Blog Posts

Blog Topics by Tags

Monthly Archives

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

ADVERTISEMENT

Onco'Zine is present here

Bookmark / Share

Join the Conversation!

Pharmceutical Business News


© 2013   Created by Peter Hofland, PhD.

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+